Calithera Biosciences Inc. (CALA) 13.41 $CALA Calithera

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 1:22 PM

Calithera Biosciences Inc. (CALA) 13.41 $CALA

Calithera Biosciences Announces Clinical Data Presentation at ASCO 2015
GlobeNewswire - Wed Apr 22, 8:00AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, will be presented at the 51 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois. Clinical results to be presented include updated data from Calithera's Phase I trial in solid tumors. Calithera will hold an investor and analyst briefing Saturday, May 30, 2015 in Chicago, Illinois at 6:30 p.m. CT.
CALA: 13.41 (-0.35)

Calithera Biosciences Highlights Results From Six Preclinical Abstracts at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Tue Apr 21, 6:45AM CDT
-Potential Biomarker Response to CB-839 Among KRAS and EGFR Mutant Cell Lines
CALA: 13.41 (-0.35)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT

SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)

BUYINS.NET: CALA SqueezeTrigger Price is $18.90. There is $860,475 That Short Sellers Still Need To Cover.
M2 - Wed Apr 15, 2:56AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Catalina Lighting Inc (NASDAQ:CALA) in real time and just received an alert that CALA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 44700 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $18.90. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
CALA: 13.41 (-0.35)

Calithera Biosciences to Present at the 14th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 8:05AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 14 Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Wednesday, April 15, 2015 at 3:40 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.
CALA: 13.41 (-0.35)

3 Stocks Breaking Out on Unusual Volume
at The Street - Fri Mar 27, 12:56PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
SWKS: 93.39 (-2.43), AXLL: 43.43 (+0.25), CALA: 13.41 (-0.35)

Calithera Biosciences (CALA) Crumbles: Stock Falls by 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 7:55AM CDT
Calithera Biosciences saw a big move last session, as the company’s shares fell by 7%. This reverses the recent trend for CALA as the stock is now up around 22%
LCI: 67.40 (unch), CALA: 13.41 (-0.35)

Calithera Biosciences reports FQ4 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:22PM CDT

CALA: 13.41 (-0.35)

Calithera Biosciences Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 26, 3:05PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal fourth quarter and year ended December 31, 2014. As of December 31, 2014, cash and cash equivalents totaled $102.0 million.
CALA: 13.41 (-0.35)

Pre-Earnings Calithera Biosciences Inc. Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Mar 26, 6:00AM CDT
Calithera Biosciences Inc. (NASDAQ: CALA) based in San Francisco, CA a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer will be reporting fourth quarter and year-end earnings this morning. Anticipation of this release has driven the recent investor interest in the shares of Calithera. Rollercoaster - like activity was observed for the past 4 trading days.
CALA: 13.41 (-0.35)

Calithera Biosciences (CALA) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise roughly 19% on the day.
LCI: 67.40 (unch), CALA: 13.41 (-0.35)

Calithera Biosciences to Report Fourth Quarter and Year-End 2014 Financial Results on Thursday, March 26, 2015
GlobeNewswire - Fri Mar 20, 7:30AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Thursday, March 26, 2015. Company management will host a conference call on Thursday, March 26, 2015 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
CALA: 13.41 (-0.35)

Calithera Biosciences Announces Five Data Presentations at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Wed Mar 18, 3:30PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the upcoming presentation of five preclinical abstracts, highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. Details for the two oral presentations and three poster presentations are as follows:
CALA: 13.41 (-0.35)

Calithera Biosciences (CALA) Jumps: Stock Moves Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise over 10% on the day.
LCI: 67.40 (unch), CALA: 13.41 (-0.35)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:15AM CST

NGL: 28.06 (+0.36), FNSR: 20.98 (-0.16), SSH: 4.33 (-0.03), YY: 63.87 (+0.95), CNAT: 6.66 (-0.15), ASTI: 1.19 (+0.05), CLDN: 13.68 (-0.26), AXN: 1.71 (+0.02), VMEM: 3.74 (-0.03), BLRX: 2.10 (-0.02), GENE: 4.70 (-0.13), OREX: 7.36 (-0.08), SKUL: 11.13 (-0.03), CALA: 13.41 (-0.35), AVEO: 1.92 (-0.08), MSO: 5.96 (-0.02), GALE: 1.45 (+0.02), CKP: 10.84 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ABCmouse Teams with Netflix for Global Learning Expansion

ABCmouse Reinvents Learning in a Digital Age Just when you thought the kids’ education scene couldn’t get any tech-savvier, ABCmouse swoops in with a new game changer. In collaboration with Netflix, the folks at Age of Learning have launched a slick mobile game that’ll keep the kiddies learning in the palm of their hands. Screen time just turned into brain-building...

Construction Partners' Georgia Move Bolsters Growth

CPI's Strategic Expansion into Georgia Here's an acquisition to keep your eye on: Construction Partners, Inc. (NASDAQ: ROAD), also known in the corridors of trading as CPI, is making a move that many of us in the business have been anticipating for some time. They’ve wrapped up the acquisition of Piedmont Paving, Inc., a Newnan, Georgia-based company. Now, for most...

Sabre's Q3 Earnings: What Investors Need to Know

Unpacking Sabre's Latest Financial Reveal Sabre Corporation, that familiar name in travel tech, let the third quarter numbers out of the bag. Published fresh off the wire on November 5th, this round of figures covers the books up until September 30, 2026. If you're wired into NASDAQ:SABR, this is your bread and butter for the quarter. The figures, straight from Sabre's...

Texas Alcohol Crash Stats Expose Reckless Drinking Scene

Staggering Numbers From Texas Crashes Reveal a Sobering Truth When you peel back the layers on Texas's latest alcohol-related crash data, you're looking at a grim picture painted by Grossman Law Offices. In a state that's no stranger to big numbers and even bigger drinks, finding that half of these crashes had a blood alcohol content (BAC) over twice the legal limit makes...

Mesirow's Strategic Advisory on Canworks-Mason Wells Sale

A New Chapter for Canworks When companies change hands, it's more than just swapping logos on a building; it's about strategic alignment and market maneuvering. Canworks, a rising star in the direct-to-aluminum-can digital printing arena, is the latest player to shift gears by selling to Mason Wells. The whole deal, spearheaded by Mesirow's ace advisory team, represents a...

Ophthalmic Equipment Market Set for Growth Surge by 2031

Eyeing the Road Ahead: Vital Market Growth Insights We've got ourselves a sector on the move. The ophthalmic equipment market, pegged at USD 21.2 billion in 2026, is set to climb up to a whopping USD 30.5 billion by 2031. Knowing that it’s growing at a steady clip of 7.5% CAGR over these years, there’s more than just a glimmer of opportunity for those savvy enough to...

Endava Faces Class Action for Securities Violation

Endava's Legal Storm Clouds Gather Well, well, looks like Endava plc (NYSE: DAVA) has found itself knee-deep in a legal quagmire, thanks to some not-so-transparent financial antics. Investors are up in arms, and the fine folks at DJS Law Group are stepping in, filing a class action lawsuit against Endava for overstating their financial health. They allege that Endava made...

FCS Awareness Day Aims to Illuminate a Hidden Struggle

The Underreported Battle of FCS Patients There's something to be said about bringing the invisible fights to the forefront—putting the unseen struggles of real people on public display. This Friday, Nov. 6, 2026, the Foundation for Triglyceride Disorders is doing just that with FCS Awareness Day. Their mission: spark conversations and shine a light on Familial...

Zetrix AI's KYA Service: Trust in AI Agents Expands

A Trust Leap for AI Agents We’re standing at a peculiar crossroads where AI is being handed the car keys to drive us through the next digital frontier. Now, Zetrix AI, teaming up with the China Academy of Information and Communications Technology (CAICT), has dropped a new bomb in the AI landscape—a 'Know Your Agent' (KYA) service aimed at reining in the wild...

Expansive Moves to Salt Lake City for Flexible Growth

Breaking New Ground in Utah Alright, letting another workspace provider muscle into a new territory isn't groundbreaking anymore, but with Expansive breaking into Salt Lake City, there's more than meets the eye. We're talking about expanding not just geographically but also strategically in Utah's fertile grounds—characterized by a booming local economy and escalating...